EPISODE · Jul 31, 2020 · 18 MIN
001 Expedited Drug Development - James Mencel
from CMC Live - Chemistry, Manufacturing & Controls · host Ed Narke, James Mencel, Meranda Parascandola
What We Covered00:23 – James discusses regulations and the importance of starting with big ideas when it comes to expedited drug development programs05:44 – Breakthrough designations that occur as a result of expedited drug development programs08:20 – When a sponsor should consider applying for expedited drug development11:14 – James speaks to his unique background and experiences with CMC including obstacles and challenges that CMC faces15:02 – What companies can do to get ahead of the curve when it comes to drug development18:10 – Ed and Miranda thank James for joining the showTweetable Quotes“When you are in a program that gets expedited, the attention is for the program to move quickly. And there are several ways in which it can move quickly. But almost all of them lead to a very shortened timeframe for CMC. So what it gets you is the FDA’s aware that there is stress on CMC.” “If you know you’ve got a receptor site – a validated model – some sponsors know from the outset they’re going to approach the FDA even before they go into Phase One because they have a receptor site model. And if they get a model that hits then they’re going to request some sort of expedited status.” “The first question to ask yourself is, ‘Can this process do the job?’ Because, if this program goes expedited, this process that I’m running right now may be the commercial process whether I like it or not.” Relevant LinksLeadership - https://dsinpharmatics.com/leadership/#leadershipProject Management - https://dsinpharmatics.com/leadership#projectmanagementAnalytical - https://dsinpharmatics.com/leadership#analyticalDrug Substance - https://dsinpharmatics.com/leadership#drugsubstanceDrug Product - https://dsinpharmatics.com/leadership#drugproductRegulatory - https://dsinpharmatics.com/leadership#regulatoryQuality Assurance - https://dsinpharmatics.com/leadership#qualityassuranceBiologics & Microbiology - https://dsinpharmatics.com/leadership#biologicsFormulation & Clinical Ops - https://dsinpharmatics.com/leadership#formulationDesign Space InPharmatics - LinkedInDesign Space InPharmatics - TwitterEdward Narke on LinkedIn
What this episode covers
DSInPharmatics' Senior Drug Substance Consultant, James Mencel, joins the show to share his background with CMC management. In this episode, Ed, Meranda and James discuss the impact that expedited drug development programs have had on the pharma industry. They break down regulations, breakthrough designations and best practices when it comes to these programs.
NOW PLAYING
001 Expedited Drug Development - James Mencel
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m